{"id":666128,"date":"2023-09-04T19:42:02","date_gmt":"2023-09-04T19:42:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=666128"},"modified":"2023-09-04T19:42:02","modified_gmt":"2023-09-04T19:42:02","slug":"fragile-x-syndrome-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-202332-delveinsight-zynerba-alcobra-prilenia-autifony-novartis-healx-lysogene-actinogen-roche","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/fragile-x-syndrome-market-to-grow-at-a-substantial-growth-rate-during-the-forecast-period-202332-delveinsight-zynerba-alcobra-prilenia-autifony-novartis-healx-lysogene-actinogen-roche_666128.html","title":{"rendered":"Fragile X Syndrome Market to Grow at a Substantial Growth Rate During the Forecast Period (2023-32) – DelveInsight | Zynerba, Alcobra, Prilenia, Autifony, Novartis, Healx, Lysogene, Actinogen, Roche"},"content":{"rendered":"
\n
\"Fragile<\/a><\/div>\n
\n
Delveinsight Business Research LLP<\/div>\n<\/div>\n<\/div>\n
Fragile X Syndrome Market size in the 7MM was USD 45 Million in 2021, which is anticipated to grow by 2032. As per DelveInsight, the Fragile X Syndrome Market is anticipated to evolve immensely in the coming years owing to the rising prevalent population of Fragile X Syndrome (FXS) patients in the 7MM and the launch of new therapies in the market.<\/div>\n

Companies like Zynerba Pharmaceuticals, Confluence Pharmaceuticals, Tetra Therapeutics, Ovid Therapeutics, and Neuren Pharmaceuticals<\/strong> are coming up with novel therapeutic approaches that can entirely change the treatment landscape of Fragile X Syndrome (FXS).<\/em><\/p>\n

DelveInsight’s “Fragile X Syndrome Market Insights, Epidemiology, and Market Forecast 2032<\/strong>” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Fragile X Syndrome market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).<\/p>\n

The report covers emerging Fragile X Syndrome drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Fragile X Syndrome treatment practice\/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. <\/p>\n

Fragile X Syndrome: An Overview<\/strong><\/p>\n

Fragile X Syndrome (FXS) is a genetic disease due to a CGG trinucleotide expansion, named full mutation (greater than 200 CGG repeats), in the fragile X mental retardation 1 gene locus Xq27.3. It leads to a hypermethylated region in the gene promoter, therefore, silencing it and lowering the expression levels of the fragile X mental retardation 1, a protein involved in synaptic plasticity and maturation. Also, FXS is considered the most common inherited cause of intellectual disability and the second most prevalent cause after Down syndrome.<\/p>\n

At birth, FXS neonates often exhibit no clinical signs of FXS with most parameters (e.g., head circumference, weight, and height) in the normal range. In early childhood FXS, physical and developmental features become more apparent, including developmental delays, psychomotor delays, intellectual disabilities, and a long face with prominent ears and flat feet. The behavioral phenotype of FXS includes significant anxiety, attention deficit hyperactivity disorder (ADHD), and hyperarousal to sensory stimuli.<\/p>\n

Currently, there is no treatment for FXS, but some treatments help minimize the symptoms of the condition The treatment regimen of FXS includes the use of stimulants, selective serotonin reuptake inhibitors (SSRIs), atypical antipsychotics, and alpha agonists.<\/p>\n

The market is expected to grow due the factors like the expected entry of emerging therapies with novel targets and pricing. Furthermore, the impending products such as Zygel, Acamprosate, BPN14770, OV101, and Trofinetide<\/strong> are anticipated to expand the market with more penetration in the 7MM markets.<\/p>\n

Fragile X Syndrome Market Key Facts<\/strong><\/p>\n